Endocyte Investor Sues Over Faulty Drug In $1B Merck Deal
Endocyte Inc.'s board of directors lied about an ineffective cancer drug at the heart of a $1 billion deal with Merck & Co. to inflate the company's stock ahead of a public...To view the full article, register now.
Already a subscriber? Click here to view full article